QTTB

+ Watchlist + Portfolio

Q32 Bio Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $15.84
52-Week Range: $1.62 – $23.57
Market Cap: $472.14M
P/E (TTM): 5.05
EPS (TTM): 3.14
Dividend Yield: —

Advanced Metrics

Price/Book: 3.55
PEG Ratio: —
Return on Equity: 72.14%
Return on Assets: 14.74%
Gross Margin: 73.30%
Operating Margin: 39.94%
Profit Margin: 62.87%
Current Ratio: 20.30
Debt/Equity: 0.05
Total Debt: $5.30M
Free Cash Flow: $19.39M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $370.57M

QTTB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$6.65M	-$6.65M	$0.00	$53.74M
Research & Development	$35.81M	$31.73M	$48.14M	$19.16M
Selling, General & Admin	$10.06M	$9.88M	$17.96M	$17.68M
Operating Expenses	$45.88M	$41.60M	$66.10M	$36.84M
Operating Income	-$39.23M	-$48.26M	-$66.10M	$16.90M
EBITDA	-$38.85M	-$47.76M	-$44.50M	$31.31M
Pretax Income	-$42.75M	-$53.42M	-$46.09M	$29.82M
Income Tax	$62.00K	$318.00K	$21.00K	$0.00
Net Income	-$42.81M	-$53.74M	-$47.73M	$29.82M
Diluted EPS	-3.59	-4.51	-6.58	2.42
Diluted Shares	11.93M	11.93M	9.66M	12.31M

QTTB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$43.89M	$25.62M	$77.97M	$48.30M
Receivables	$1.06M	$755.00K	$555.00K	$5.39M
Current Assets	$46.85M	$28.72M	$81.88M	$55.05M
Total Assets	$61.77M	$47.06M	$92.33M	$61.78M
Current Liabilities	$57.87M	$14.11M	$16.46M	$11.35M
Long-Term Debt	$5.07M	$43.18M	$9.56M	$3.47M
Total Debt	$44.73M	$50.84M	$18.90M	$15.34M
Total Liabilities	$192.49M	$229.98M	$86.66M	$19.76M
Retained Earnings	-$133.34M	-$187.08M	-$234.81M	-$204.99M
Shareholders' Equity	-$130.71M	-$182.92M	$5.67M	$42.01M
Working Capital	-$11.01M	$14.61M	$65.41M	$43.70M
Net Debt	—	$18.44M	—	—

QTTB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$10.96M	-$18.68M	-$67.72M	-$33.54M
Capital Expenditure	-$2.48M	-$5.00K	-$75.00K	—
Free Cash Flow	-$13.44M	-$18.68M	-$67.79M	-$33.54M
Depreciation & Amortisation	$370.00K	$499.00K	$487.00K	$391.00K
Stock-Based Compensation	$1.24M	$1.43M	$4.39M	$5.25M
Investing Cash Flow	-$2.47M	-$5.00K	$19.93M	$7.00M
Financing Cash Flow	$30.07M	$406.00K	$95.14M	-$3.13M
Net Change in Cash	$16.65M	-$18.28M	$47.35M	-$29.67M

QTTB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$53.74M	$0.00
Research & Development	$7.12M	$5.16M	$3.56M	$3.31M	$3.22M
Selling, General & Admin	$5.10M	$4.01M	$4.02M	$4.54M	$4.50M
Operating Expenses	$12.23M	$9.17M	$7.58M	$7.86M	$7.72M
Operating Income	-$12.23M	-$9.17M	-$7.58M	$45.88M	-$7.72M
EBITDA	-$12.11M	-$9.10M	-$7.00M	$58.02M	-$7.63M
Pretax Income	-$11.03M	-$9.49M	-$7.39M	$57.73M	-$7.61M
Income Tax	$0.00	$0.00	—	—	—
Net Income	-$11.03M	-$9.49M	-$7.39M	$57.73M	-$7.61M
Diluted EPS	-0.90	-0.78	-0.60	—	-0.54
Diluted Shares	12.20M	12.20M	12.24M	—	14.10M

QTTB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$65.48M	$54.83M	$49.04M	$48.30M	$50.75M
Receivables	$555.00K	$555.00K	$556.00K	$5.39M	$5.39M
Current Assets	$68.63M	$58.32M	$50.81M	$55.05M	$57.20M
Total Assets	$79.07M	$66.12M	$57.78M	$61.78M	$63.67M
Current Liabilities	$14.58M	$11.53M	$11.11M	$11.35M	$10.67M
Long-Term Debt	$8.04M	$6.52M	$5.00M	$3.47M	$1.94M
Total Debt	$18.80M	$18.70M	$17.02M	$15.34M	$13.65M
Total Liabilities	$83.08M	$78.35M	$76.23M	$19.76M	$17.36M
Retained Earnings	-$245.84M	-$255.33M	-$262.72M	-$204.99M	-$212.60M
Shareholders' Equity	-$4.01M	-$12.23M	-$18.45M	$42.01M	$46.31M
Working Capital	$54.05M	$46.79M	$39.70M	$43.70M	$46.53M

QTTB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$12.48M	-$10.65M	-$4.23M	-$6.18M	-$6.34M
Free Cash Flow	-$12.48M	-$10.65M	-$4.23M	-$6.18M	-$6.34M
Depreciation & Amortisation	$119.00K	$91.00K	$91.00K	$90.00K	$90.00K
Stock-Based Compensation	$1.34M	$1.27M	$1.18M	$1.47M	$1.55M
Investing Cash Flow	$0.00	$0.00	$0.00	$7.00M	$0.00
Financing Cash Flow	$0.00	$0.00	-$1.56M	-$1.56M	$8.80M
Net Change in Cash	-$12.48M	-$10.65M	-$5.79M	-$742.00K	$2.45M

Market Snapshot

About

Q32 Bio is a clinical-stage biotechnology company developing therapies targeting the complement pathway for immune-mediated diseases. The company focuses on conditions like atopic dermatitis, asthma, and inflammatory bowel disease. Q32 Bio uses a precision approach to modulate specific complement components, aiming for targeted efficacy with reduced side effects compared to broader immunosuppression.